Opinion|Videos|January 21, 2025
Multidisciplinary Strategies for Optimizing Care in Unresectable Stage III NSCLC
This video segment discusses defining resectability for Stage III lung cancer, the importance of a multidisciplinary approach to decision-making involving surgical, medical, radiation oncology, and diagnostic teams, and the role of patient engagement in tailoring treatment plans to individual priorities, risks, and physiological suitability.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What multidisciplinary coordination is vital to optimizing care for patients with unresectable stage III NSCLC?
- Which specialists should be involved and what is their role on the treatment team?
- How do you ensure the multidisciplinary team is aligned on diagnosis, risk assessment, and treatment goals for each patient?
- What is the importance of including the patient in these treatment goal discussions?
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
EU Approval Reccomended by CHMP for Senaparib in First-Line Advanced Ovarian Cancer
3
CHMP Backs Perioperative Pembrolizumab Plus Enfortumab Vedotin for Resectable MIBC
4
Dr Gilbert on the Efficacy of Relacorilant Plus Nab-Paclitaxel in Ovarian Cancer
5